Objectives: Ceftriaxone resistance in Neisseria gonorrhoeae is a major public health concern globally because a high-dose (1 g) injection of ceftriaxone is the only remaining option for empirical monotherapy of gonorrhoea. The ceftriaxone-resistant gonococcal strain FC428, cultured in Osaka in 2015, is suspected to have spread nationally and internationally. We describe the complete finished genomes of FC428 and two closely related isolates from Osaka in 2015, and examine the genomic epidemiology of these isolates plus three ceftriaxone-resistant gonococcal isolates from Osaka and Hyogo in 2016-17 and four ceftriaxone-resistant gonococcal isolates cultured in 2017 in Australia, Canada and Denmark.

Methods: During 2015-17, we identified six ceftriaxone-resistant gonococcal isolates through our surveillance systems in Kyoto, Osaka and Hyogo. Antimicrobial susceptibility testing (six antimicrobials) was performed using Etest. Complete whole-genome sequences of the first three isolates (FC428, FC460 and FC498) from 2015 were obtained using PacBio RS II and Illumina MiSeq sequencing. The three complete genome sequences and draft genome sequences of the three additional Japanese (sequenced with Illumina MiSeq) and four international ceftriaxone-resistant isolates were compared.

Results: Detailed genomic analysis suggested that the Japanese isolates (FC428, FC460, FC498, KU16054, KM383 and KU17039) and the four international MLST ST1903 isolates from Australia, Canada and Denmark formed four linked subclades.

Conclusions: Using detailed genomic analysis, we describe the clonal expansion of the ceftriaxone-resistant N. gonorrhoeae strain FC428, initially identified in 2015 in Japan, and closely related isolates. FC428 and its close relatives show some genomic diversity, suggesting multiple genetic subclades are already spreading internationally.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkz129DOI Listing

Publication Analysis

Top Keywords

ceftriaxone-resistant gonococcal
16
strain fc428
12
closely isolates
12
gonococcal isolates
12
isolates fc428
12
isolates
11
clonal expansion
8
neisseria gonorrhoeae
8
gonorrhoeae strain
8
osaka 2015
8

Similar Publications

Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015-24: an observational analysis.

J Antimicrob Chemother

December 2024

Blood Safety, Hepatitis, STI & HIV Division, United Kingdom Health Security Agency, London, UK.

Objectives: Since June 2022, there has been a rise in the number of ceftriaxone-resistant Neisseria gonorrhoeae cases detected in England (n = 15), of which a third were XDR. We describe the demographic and clinical details of the recent cases and investigate the phenotypic and molecular characteristics of the isolates. For a comprehensive overview, we also reviewed 16 ceftriaxone-resistant cases previously identified in England since December 2015 and performed a global genomic comparison of all publicly available ceftriaxone-resistant N.

View Article and Find Full Text PDF

Background: Doxycycline post-exposure prophylaxis (PEP) has been shown to be efficacious for the prevention of bacterial sexually transmitted infections, but resistance implications for Neisseria gonorrhoeae remain unknown. We aimed to use a mathematical model to investigate the anticipated impact of doxycycline PEP on the burden of gonorrhoea and antimicrobial resistance dynamics in men who have sex with men (MSM) in the USA.

Methods: Using a deterministic compartmental model, characterising gonorrhoea transmission in a US MSM population comprising three sexual activity groups defined by annual partner turnover rates, we introduced doxycycline PEP at various uptake levels (10-90%) among those with high sexual activity.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists studied how to fight bacteria that are resistant to a medicine called ceftriaxone.
  • They tested different drugs to see if they could work together with ceftriaxone to stop the bacteria from becoming resistant.
  • The results showed that two specific drugs, zoliflodacin and pristinamycin, could help reduce the chances of ceftriaxone resistance spreading.
View Article and Find Full Text PDF

High-level ceftriaxone resistance due to transfer of penA allele 60.001 into endemic gonococcal lineages in Hangzhou, China.

J Antimicrob Chemother

November 2024

Department of Microbiology, and Department of Dermatology of Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Article Synopsis
  • The study examines the prevalence and resistance of Neisseria gonorrhoeae strains in Hangzhou, China, focusing on the high-level ceftriaxone-resistant FC428 clone and its resistance determinant, penA allele 60.001, from 2020 to 2022.
  • Out of 209 gonococcal isolates tested, 16% showed resistance to ceftriaxone, with 6.7% exhibiting high-level resistance, particularly in isolates containing penA allele 60.001.
  • The findings highlight ongoing transmission of resistant strains and raise public health concerns regarding the spread of the resistance trait among local endemic lineages.
View Article and Find Full Text PDF

Disseminated gonococcal infection during two decades in the university hospital, Thailand.

Asian Biomed (Res Rev News)

June 2024

Division of Rheumatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Article Synopsis
  • Disseminated gonococcal infection (DGI) is characterized by a combination of polyarthritis, tenosynovitis, and dermatitis, with limited clinical data available from Thailand.
  • A study at King Chulalongkorn Memorial Hospital analyzed records from 2002 to 2019, identifying 41 DGI patients, with a median age of 30 years and an equal male-to-female ratio.
  • Most patients exhibited symptoms like fever and arthritis, with a favorable treatment response, and all tested strains were susceptible to ceftriaxone, indicating no cases of ceftriaxone resistance.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!